Phase 2 Breast Neoplasms trials recruiting now

All Breast Neoplasms trials, every phase

Other phases for Breast Neoplasms

Phase 2 Breast Neoplasms trials

• 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
  NCT06335069 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
  NCT04641247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 89 locations
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 295 locations
• Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
  NCT04993014 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
  NCT07581834 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
  NCT04983121 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
  NCT02476786 · Phase: Phase 2 · Ages: 70 Years and older · Sex: Female · 1 location
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Neoadjuvant Radiation in Locally Advanced Breast Cancer
  NCT05479409 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
  NCT05485766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  NCT07222215 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
  NCT06974604 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
  NCT06464913 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
  NCT05386108 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 86 locations
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT05981014 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
  NCT06797635 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  NCT06686394 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Target-specific immunoPET Imaging of Breast Cancer
  NCT06715826 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Tirzepatide Weight Loss for MRD+ Early Breast Cancer
  NCT06517212 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
  NCT05978648 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.